{"entity":{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","aka":[],"tldr":"Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.","summary":"Amer Zeidan leads the myelodysplastic syndromes programme at Yale Cancer Center. He was the lead investigator of VERONA, the phase 3 trial of venetoclax plus azacitidine against azacitidine alone in newly diagnosed higher-risk MDS, and presented its results in 2024: the combination did not improve overall survival. He publishes widely on MDS treatment patterns, health outcomes and trial endpoints.","asOf":"2026-09-18","links":[],"tags":["mds","trialist"],"related":[],"cancers":["mds-higher-risk","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":["verona"],"people":[],"bottlenecks":[],"keyPapers":["paper-amer-zeidan-n-engl-j-med-2020","paper-amer-zeidan-j-clin-oncol-2021","paper-commands-luspatercept-mds-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Myelodysplastic syndromes","Acute myeloid leukaemia","Trial design and outcomes research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeidan%5BAuthor%5D"}],"papers":[{"title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/nejmoa1908892","doi":"10.1056/nejmoa1908892","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 420 citations on Europe PMC."},{"title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/jco.20.01632","doi":"10.1200/jco.20.01632","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 150 citations on Europe PMC."},{"title":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)00874-7","doi":"10.1016/S0140-6736(23)00874-7","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 140 citations on Europe PMC."}],"orcid":"0000-0001-7017-8160"},"route":"/people/amer-zeidan/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"institution":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/"}],"trial":[{"id":"verona","kind":"trial","name":"VERONA","route":"/trials/verona/"}],"paper":[{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/"},{"id":"paper-amer-zeidan-n-engl-j-med-2020","kind":"paper","name":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","route":"/key-papers/paper-amer-zeidan-n-engl-j-med-2020/"},{"id":"paper-amer-zeidan-j-clin-oncol-2021","kind":"paper","name":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","route":"/key-papers/paper-amer-zeidan-j-clin-oncol-2021/"}]}}